Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. May 15, 2023; 15(5): 859-877
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart of selection of study participants. HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Subsequent therapies for patients with hepatocellular carcinoma with different levels of China Liver Cancer staging. LR: Liver resection; RFA: Radiofrequency ablation; LT: Liver transplantation; TACE: Transcatheter arterial chemoembolization.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Overall survival rate. A: Overall survival rate in patients with different levels of China Liver Cancer staging (P < 0.001); B: Patients who did and did not receive treatment recommended by the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (P = 0.344).
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Tumor-free survival rate. A: Tumor-free survival rate after liver resection in patients with hepatocellular carcinoma with and without guideline compliance (P < 0.001); B: Tumor-free survival rate after liver resection among patients with different China Liver Cancer staging levels. Early stage vs middle stage, P < 0.001; early stage vs late stage, P < 0.001; middle stage vs late stage, P = 0.099.